SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments ...
Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate (ORR) ...
Chrome Canary’s New Tab Page shows an AI-style box with AI Mode and a + button to add tabs, images, or files before you ask ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback